<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308501</url>
  </required_header>
  <id_info>
    <org_study_id>14-100-0012</org_study_id>
    <nct_id>NCT02308501</nct_id>
  </id_info>
  <brief_title>A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ORA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft ® as Measured by
      In-Vivo Confocal Microscopy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conjunctival Inflammation</measure>
    <time_frame>Day 1 - Day 2</time_frame>
    <description>scored on a 0 to 4 scale, 0= none and 4= white blood cell adherence and migration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular itching</measure>
    <time_frame>Day 1 - Day 2</time_frame>
    <description>scored on a 0 to 4 scale, 0=none and 4=incapacitating itch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ciliary, Conjunctival, and Episcleral redness</measure>
    <time_frame>Day 1 - Day 2</time_frame>
    <description>scored on a 0 to 4 scale, 0=none 4=extremely severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eyelid swelling</measure>
    <time_frame>Day 1 - Day 2</time_frame>
    <description>scored on a 0 to 3 scale, 0=none 3=severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemosis</measure>
    <time_frame>Day 1 - Day 2</time_frame>
    <description>scored on a 0 to 4 scale, 0=none 4=severe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Lastacaft ®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop Lastacaft® in right eye and one drop Tears Naturale® in left eye once on Day 1 and once on Day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tears Naturale ®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop Tears Naturale® in right eye and one drop Lastacaft® in left eye once on Day 1 and once on Day 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lastacaft ®</intervention_name>
    <arm_group_label>Lastacaft ®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tears Naturale ®</intervention_name>
    <arm_group_label>Tears Naturale ®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a positive history of ocular allergies and a positive skin test to protocol
             defined allergens

          -  Have a positive CAC reaction at Visit 1

          -  Have a positive conjunctival inflammation score at Visit 1

        Exclusion Criteria:

          -  May not use disallowed medications in specified washout period

          -  May not have an ocular or system disease the investigator feels with impact subject
             safety or trial parameters

          -  May not have active ocular infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextrans</mesh_term>
    <mesh_term>Alcaftadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

